EXACT SCIENCES

First Quarter 2020 Earnings Call

May 6, 2020

Safe harbor statement

Forward-Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission. Specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections of forward-looking statements.

Non-GAAP Disclosure

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the Unites States (GAAP) and using certain non-GAAP financial measures. The company presents EBITDA, adjusted EBITDA, as well as adjusted gross margin and adjusted gross profit. The company believes that these non-GAAP measures are useful in evaluating the company's operating performance. The company uses this non-GAAP financial information to evaluate ongoing operations and for internal planning and forecasting purposes. For additional information and a reconciliation of these non-GAAP measures to GAAP, see the Company's press release issued in connection with this presentation.

3 key topics

1. Near-term challenges presented by coronavirus and steps to respond

2. Positioning to provide smarter solutions to patients and providers

3. Actions we're taking to deliver value over the long term

First quarter 2020 financials

	Q1 2020	Q1 2019
Revenue	$347.8 million	$162.0 million
Screening	$219.5 million	$162.0 million
Precision Oncology*	$128.4 million	--
Gross margin	71%	73%
Non-GAAP gross margin	77%	74%
Operating expense	$325.2 million	$186.5 million
Ending cash balance	$1.2 billion	$1.3 billion

*Precision Oncology primarily includes revenue from the Genomic Health acquisition completed in November 2019
Non-GAAP gross margin excludes amortization of acquisition-related intangibles
Operating expense includes R&D, S&M, and G&A, and excludes amortization of acquired intangibles

Updated 2020 Priorities

Get People Tested

Take Care of our Customers

Preserve Financial Strength

Committed to delivering critical answers to patients

Taking action to ensure employee safety and continue processing tests

Work from home
mandate

Coronavirus
testing

Virtual
field sales calls

Continuity
plans

Accelerated availability of telehealth resources

Increasing awareness with targeted ads

- Social
- Digital
- Television

Oncotype answering important treatment questions

oncotype DX®
Breast Recurrence Score



Identify up to

85%

of women with early breast cancer who can be spared chemotherapy

oncotype DX®
Genomic Prostate Score



Change treatment for

1/4

men with low- and intermediate-risk prostate cancer

Sources: Sparano et al. N Engl J Med. 2018; Geyer et al. NPJ Breast Cancer. 2018; Badani et al. Urol Pract. 2015

Providing smarter answers across the cancer continuum

Recently closed Paradigm acquisition

The Paradigm advantage

Fast answers

5 days or less from sample receipt to result

High test completion rate

less sample input required

Broad target coverage

markers associated with >90 FDA-approved therapies

Helping support coronavirus testing capacity

Highlights R&D, laboratory, and manufacturing abilities

Leading, global, advanced cancer diagnostics company



★ Headquarters ● Offices

Experienced team & multiple products

Global infrastructure

Financial strength

EXACT
SCIENCES